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Abstract
Introduction: Mammographic breast density is a highly heritable (h
2 > 0.6) and strong risk factor for breast cancer.
We conducted a genome-wide linkage study to identify loci influencing mammographic breast density (MD).
Methods: Epidemiological data were assembled on 1,415 families from the Australia, Northern California and
Ontario sites of the Breast Cancer Family Registry, and additional families recruited in Australia and Ontario. Families
consisted of sister pairs with age-matched mammograms and data on factors known to influence MD. Single
nucleotide polymorphism (SNP) genotyping was performed on 3,952 individuals using the Illumina Infinium 6K
linkage panel.
Results: Using a variance components method, genome-wide linkage analysis was performed using quantitative traits
obtained by adjusting MD measurements for known covariates. Our primary trait was formed by fitting a linear model
to the square root of the percentage of the breast area that was dense (PMD), adjusting for age at mammogram,
number of live births, menopausal status, weight, height, weight squared, and menopausal hormone therapy. The
maximum logarithm of odds (LOD) score from the genome-wide scan was on chromosome 7p14.1-p13 (LOD = 2.69;
63.5 cM) for covariate-adjusted PMD, with a 1-LOD interval spanning 8.6 cM. A similar signal was seen for the covariate
adjusted area of the breast that was dense (DA) phenotype. Simulations showed that the complete sample had
adequate power to detect LOD scores of 3 or 3.5 for a locus accounting for 20% of phenotypic variance. A modest
peak initially seen on chromosome 7q32.3-q34 increased in strength when only the 513 families with at least two sisters
below 50 years of age were included in the analysis (LOD 3.2; 140.7 cM, 1-LOD interval spanning 9.6 cM). In a subgroup
analysis, we also found a LOD score of 3.3 for DA phenotype on chromosome 12.11.22-q13.11 (60.8 cM, 1-LOD interval
spanning 9.3 cM), overlapping a region identified in a previous study.
Conclusions: The suggestive peaks and the larger linkage signal seen in the subset of pedigrees with younger
participants highlight regions of interest for further study to identify genes that determine MD, with the goal of
understanding mammographic density and its involvement in susceptibility to breast cancer.
Introduction
Mammographic density (MD), adjusted for age and body
mass index (BMI) is a strong risk factor for breast can-
cer. The radiographic appearance of the breast on mam-
mography varies among women and reflects differences
in breast tissue composition and X-ray attenuation
characteristics [1]. Fat is radiologically lucent [1] and
appears dark on a mammogram, whereas connective
and epithelial tissues are radiologically dense and appear
light. The area of radiological dense tissue is often
expressed as a percentage of the total breast area (per-
cent mammographic density (PMD)). Compared to
women of the same age and BMI with little or no den-
sity, PMD of ≥75% is associated with a four- to five-fold
increased risk of breast cancer and an increased risk of
all of the proliferative lesions that are thought to be
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cancer risk associated with high PMD does not differ by
age, menopausal status, or race/ethnicity and cannot be
explained by the ‘masking’ of cancers by dense tissue
[3]. Extensive MD is relatively common and estimates of
the associated attributable risk suggest that about a
third of breast cancer may be explained by density in
more than 50% of the breast [4,5].
Twin studies have shown that, after adjustment for
other factors such as age, parity, menopausal status,
body weight and hormonal use, about 60% of the var-
iance in PMD is explained by genetic factors [6,7]. Both
the dense area of the mammogram and the non-dense
area have been found to be heritable to a degree similar
to PMD. About two thirds of the negative correlation
between dense and non-dense area was explained by the
same genetic factors influencing both traits, but in
opposing directions [8]. To find genetic determinants of
variation in MD, we have carried out a genome-wide
linkage study with over 1,400 nuclear families with the
aim of examining previously reported loci and of identi-
fying new loci that influence MD.
Materials and methods
Recruitment of study subjects
Families consisting of at least two sisters were assembled
from several family registries and cohorts: families from
Ontario, Australia and Northern California enrolled in
the Breast Cancer Family Registry (BCFR) [9], dizygous
(DZ) twins participating in twin studies in Ontario and
Australia [6], families recruited in Ontario for a study of
MD in young women, families from Ontario recruited
through the ‘Weekend to End Breast Cancer’ event, and
twins recruited through the Ontario Breast Screening
Program (Table 1 and Additional file 1: supplementary
table 1). Families from the BCFR known to carry muta-
tions in BRCA1or BRCA2 were excluded; other partici-
pants were not screened. Epidemiologic data on relevant
covariates, previously obtained by questionnaire within
each of the above mentioned studies, were extracted
from existing databases and assembled. Approval for the
study was given by the Research Ethics Board of The
Hospital for Sick Children, the Institutional Review
Boards of the Cancer Prevention Institute of California
and the University Health Network, Toronto, and The
Human Research Ethics Committee of the University of
Melbourne. Informed written consent was obtained
from each participant. Participant recruitment from base
populations is described and summarized in Additional
file 1: supplementary Figure 1. In Ontario 1,137 (27%)
of 4,126 subjects contacted had complete data and were
included in the analysis. In Northern California 579
(38%) of 1,511 subjects contacted were included in the
analysis. A total of 1,537 subjects were included from
Australia from recent and ongoing recruitments that
included collection of mammograms.
Measurement of mammographic density
Mammograms were obtained from at least two sisters in
each family. If a woman had breast cancer, the selected
mammogram (from the contra breast) had been taken at
or before the diagnosis of breast cancer. We sought that
the ages at mammogram for two sisters should be
within 5 years of each other to minimize the require-
ment for age-adjustment within a sibship. This was
achieved in more than 95% of the families. The cranio-
caudal view in each mammogram was digitized and sent
to Toronto where all images were measured by one
reader (NFB) using a computer-assisted thresholding
method. Using Cumulus software, thresholds were set
that defined the edge of the breast and outlined the
areas of dense tissue. The pixels within these thresholds
defined, respectively, the total area of the breast and the
area of dense tissue (DA), from which percent density
(PMD) was calculated. The non-dense area (NDA) of
the mammogram was also calculated from these mea-
surements [10]. This measurement method has been
used to define differences in risk of breast cancer asso-
ciated with mammographic density [2-5] and generated
the evidence of heritability that motivated the present
study [6].
Images were measured in batches of approximately
100 images at a time. Within each batch, 10 images
were duplicated, placed in random order within the set,
and read twice in a blind fashion. Some images were
also re-read in different batches, in order to assess
Table 1 Recruitment of families for linkage
Study name Families, n (%) Women with complete data for analysis, n (%)
All Families 1,415 (100) 3,253 (100)
Australian site of the BCFR 70 (5.0) 174 (5.4)
Australian Twin & Sister Study 589 (41.6) 1,363 (41.9)
Northern California site of the BCFR 257 (18.2) 579 (17.8)
Ontario site of the BCFR 246 (17.4) 561 (17.3)
Ontario families from other sources 253 (17.9) 576 (17.7)
BCFR, Breast Cancer Family Registry.
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Page 2 of 13reliability of the PMD measurements both within and
between batches. The correlation between the two reads
in the same batch for PMD was estimated to be 0.90
(Additional file 1: supplementary Figure 2) and correla-
tion for DA was 0.92. In addition, there were 10 images
that were scored three times in three different batches,
and the intraclass correlation between batches was esti-
mated to be 0.902 by variance components analysis.
DNA, genotyping and data cleaning
DNA was obtained from the BCFR biorepositories or
was extracted from whole blood or lymphoblastoid cell
lines using Gentra Puregene Blood Kit (Qiagen, Inc.,
Toronto, ON, Canada) or QIAamp DNA Blood Maxi
Kit (Qiagen) according to the supplier’s instructions.
DNAs were quantified with Quant-iT PicoGreen
dsDNA Reagent (Life Technologies, Inc., Burlington,
ON, Canada) using fluorimetry measured with a Spec-
traMax Gemini EM instrument (Molecular Devices).
Genotyping for linkage analysis was performed by the
Center for Inherited Disease Research (CIDR) http://
www.cidr.jhmi.edu using the Illumina Infinium II
Human Linkage-12 panel. Out of 6,090 SNPs, 413 were
removed due to poor clustering, leaving 5,677 SNPs
with an overall genotype missing rate of 0.073%. After
examining Mendelian errors and estimating relation-
ships [11-13], 49 pedigrees were modified to create half
siblings when necessary, 6 larger pedigrees were created
by merging two families (this information was subse-
quently confirmed from source site), 1 family was
excluded due to sisters appearing unrelated, two families
were removed due to a sample mix-up, and one sibling
that appeared unrelated was removed from a larger ped-
igree (Additional file 1: supplementary Figure 3). After
adjusting the pedigree structures, genotypes demonstrat-
ing Mendelian inheritance inconsistencies [14] were set
to missing for all individuals in the families concerned;
this involved removing a total of 475 genotypes on the
autosomes. We removed all X chromosome data for six
women where all genotypes were homozygous or had
unusually high rates of missing genotypes.
Genotypes were missing in less than 20 individuals for
97.4% of the markers; and the poorest marker failed in
81 of 3,952 individuals. Ten or fewer marker genotypes
were missing in 91% of the genotyped individuals. Allele
frequencies were estimated from all genotyped indivi-
duals. Only 1.9% of the markers had minor allele fre-
quency (MAF) less than 0.10, and 76% of the markers
had MAF over 0.3; average heterozygosity across SNPs
was 43.7%. Multipoint marker informativity remained
very stable across the genome, ranging from 0.6 to 0.8.
Although self-reported race/ethnicity was available, we
estimated population structure by using Eigenstrat [15]
on one individual per family, combined with 1,207
HapMap phase 3 samples [16] from 10 populations, and
our 5,677 SNPs. SNP alleles were flipped when neces-
sary to match the strand used by CIDR. We found, as
expected, that the majority of the samples overlapped
with the HapMap CEU group, and furthermore that
self-reported race/ethnicity matched well with clusters
of Asian and African descent from the HapMap samples
(Additional file 1: supplementary figure 4). Principal
components (PCs) were estimated for all study partici-
pants from the eigenvectors, and then a Caucasian sub-
group was defined as those with the first PC ≥0.003 and
the second PC ≥0.
Physical marker locations were obtained from NCBI
Build 36 http://www.ncbi.nlm.nih.gov/. The Rutgers
linkage map was obtained from Rutgers Map Version 2
http://compgen.rutgers.edu/[17]. For markers not
included in the Rutgers data set, genetic distances were
interpolated at the Rutgers site.
Genotyping of individual single-nucleotide polymorph-
isms (SNPs) to attempt validation of association was
performed with allele-specific fluorescent probes in Taq-
man
® SNP Genotyping Assays (C_334499_10 for
rs723149 from Applied Biosystems, Foster City, CA,
USA) as recommended using a 96-well format. End-
point fluorescence was measured with the plate reader
component of the 7900HT Real Time PCR System
(Applied Biosystems) and aided by Taqman
® Genotyper
software for allele discrimination with call rates > 98%.
A portion of the samples (4%) was run in duplicate and
corresponded to individuals used in the linkage study to
assure quality control and permit assessment across
genotyping platforms. The concordances of replicate
genotypes and cross platform genotypes were > 99%.
Statistical analysis
Linkage analysis was performed using the Merlin (ver-
sion 1.1.2) [14] variance components method on MD
after adjustment for known covariates. Since variance
components linkage analysis is very sensitive to non-
normal distributions of traits [18], the MD measure-
ments were transformed to reduce skewness and shrink
outliers towards the center of the distributions. A square
root transformation was used for PMD, a log transfor-
mation for total non-dense area (NDA), and quantile
normalization was used for total dense area (DA) since
there were several extremely high values for DA. In
addition, two extremely large values for NDA were win-
sorized to the 99
th percentile. Trait distributions were
unaffected by breast cancer status as mammograms
were measured only from the opposite breast, prior to
or at a diagnosis. Linear models and generalized additive
models were used to model the relationships between
the MD scores and known covariates, and the residuals
were used in the linkage analysis. Family relationships
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models. In general, the expected relationships between
MD and covariates were seen. We also estimated herit-
ability in Merlin [14] and in SOLAR version 4.2.7 [19],
for the whole sample and for several subgroups. The
model used assumed no dominance variance, and
allowed for a polygenic effect. There were too few non-
Caucasian families to perform variance components
linkage analysis separately, however, linkage analysis was
repeated in the subgroup of families estimated to be
Caucasian by Eigenstrat [15]. To estimate whether our
linkage results were exceptional, simulations were per-
formed in Merlin for all autosomes. For these simula-
tions, the phenotypes and pedigree structures were
retained, and genotype data were generated by using the
estimated allele frequencies. Simulated genotypes were
considered unknown if actual genotypes were unknown.
Analysis of the simulated data was performed for the
residuals from the square root transformation of PMD.
Although this was primarily a linkage study, we calcu-
lated evidence for association using the orthogonal test
for quantitative traits implemented in QTDT [20] at
5,677 markers. This test focuses on within-family evi-
dence for association, is robust to any differences in
allele frequencies between families due to population
stratification, and assumes an additive genetic model.
Results
Family characteristics
There were 1,616 pedigrees assembled for this study
from existing collections, including 4,526 individuals
with DNA. Data verification and cleaning included
checking for monozygotic twin status (if monozygotic,
one twin was removed), gender consistency, whether the
mammogram was readable, whether relevant covariate
data were available, and whether reported family rela-
tionships were consistent with the genotyping. Pedigrees
were adjusted when data genotyping supported alterna-
tive relationships. A total of 1,415 families were retained
for analysis containing 6,638 individuals, of whom 4,993
were women (Additional file 1: supplementary Figure 3).
There were 3,952 genotyped individuals, including sib-
lings, parents and the sisters (3,253) with analysis infor-
mation (namely genotypes, MD measures, and
epidemiologic covariate information). Almost half the
families (47%) were recruited from Australia (Additional
file 1: supplementary table 2), 35% from Ontario and
18% from California. The families were mostly nuclear,
with 77% with three or more women, and 19% with four
or more women with complete analysis information.
Parental DNA was rarely available; neither of the par-
ents was genotyped in 84% of the families (Additional
file 1: supplementary table 2).
Participant characteristics
Although families were assembled from existing collec-
tions that involved a variety of recruitment strategies,
the women from the three geographical regions were
similar with regard to many of the major characteristics
known to impact MD (Table 2). Overall, the average age
at mammography was 53 years; 65% of the women were
post-menopausal, 38% had a history of hormone therapy
use, and 89% had been pregnant at least once. Due to
the differences in inclusion criteria of the collections,
the percentage of women who had been diagnosed with
breast cancer varied across the three sites; with 26% in
Ontario, 38% in Northern California and only 5% in
Australia. As expected, the percentage of women with
breast cancer was higher among those recruited from
the Breast Cancer Family Registry sites (Additional file
1: supplementary table 3). In Northern California where
recruitment targeted racial/ethnic minority populations
[21], the percentage of women self-reporting to be non-
Hispanic white was only 44%, whereas it was over 96%
in families from Ontario and Australia.
Phenotypes
Linear models were fit to the square root of PMD,
quantile-normalized DA, and log NDA, adjusting for
covariates known to impact MD. The expected relation-
ships with covariates were observed, with MD decreas-
ing with age at mammogram, with each live birth and
with menopause, but increasing with hormone therapy
use (Table 3; Additional file 1: supplementary table 4).
Weight had a non-linear relationship with MD. The
same models were also fit for each of the three sites,
Australia, Northern California and Ontario, separately,
in order to assess whether the relationships between
MD and covariates were comparable across sites. Differ-
ences in the magnitude of coefficients between sites
were, in general, much smaller than the coefficient stan-
dard errors (SEs), therefore no obvious differences
between sites were apparent (Table 3). Residuals were
calculated from these linear models for linkage analysis
(PMD_res, DA_res, and NDA_res, respectively).
Heritability
With the large set of assembled families, it was feasible
to evaluate heritability of MD traits for comparison to
previous estimates. Heritability estimates (0.50 for PMD,
0.50 for DA, 0.60 for NDA; Table 4) are in general
slightly lower than heritability estimated from twin stu-
dies [6]. Although heritability estimates for Australia
appeared somewhat lower than for the other two sites
for residuals based on either the square root of PMD
(0.43 for Australia, 0.50 for California, 0.56 for Ontario)
or on the DA residuals (Table 4), a 95% confidence
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includes all of the three site-specific estimates.
Genetic marker characteristics
After removing inconsistent and failed markers, 5,677
SNPs remained for analysis (See Materials and Meth-
ods). Tests for Hardy-Weinberg equilibrium (HWE) [22]
were performed using one randomly chosen genotyped
woman per family. When only Caucasian families are
included in these tests (excluding 105 families contain-
ing 315 individuals), there is no evidence for deviation
from HWE (Additional file 1: supplementary figure 5).
For this subset analysis, Caucasian ethnicity was defined
as individuals who clustered with the HapMap CEU
individuals in Eigenstrat PC analysis [15].
Genome-wide Linkage
Primary analysis
Logarithm of odds (LOD) score linkage plots for PMD,
DA and NDA are shown in Figure 1 (panels A, B and
C, respectively) for the autosomes and the X chromo-
some. The maximum LOD score from the genome-wide
scan for PMD was 2.69 on chromosome 7p14.1-p13 (at
63.5 cM; 46.5 Mb, NCBI Build 36.3) with a 1-LOD drop
interval from 58.5 cM to 67.2 cM. A peak at the same
location was also observed for DA (peak LOD 2.69 at
64.9 cM, 1-LOD interval 60.0-68.6). Another peak (LOD
= 2.44) was also found on chromosome 17 for PMD.
Among 100 autosome-wide simulations under the null
hypothesis, more than half of the simulations indicated
a maximum LOD score larger than 2.5 and one third
Table 2 Description of individuals with complete information
All sites Australia Northern California Ontario
Women, number 3,253 1,537 579 1,137
Age at mammogram, year 52.8 (8.7) 54.1 (8.9) 51.1 (8.3) 52.0 (8.3)
Self-reported ethnicity, n (%)
Non-Hispanic white 2,843 (87.4) 1,495 (97.3) 255 (44.0) 1,093 (96.1)
Black 89 (2.7) 0 89 (15.5) 0
East Asian 127 (3.9) 0 119 (20.6) 8 (0.7)
Other/Mixed 189 (5.8) 38 (2.2) 116 (20.0) 35 (3.1)
Age at menarche, year 12.9 (1.5) 13.0 (1.6) 12.8 (1.5) 12.8 (1.5)
Pregnant ever, n (%) 2,889 (88.8) 1,402 (91.2) 496 (85.7) 991 (87.2)
Number of live births, n (%)
0 489 (15.0) 187 (12.2) 123 (21.2) 179 (15.7)
1 314 (9.7) 115 (7.5) 88 (15.2) 111 (9.8)
2 1,165 (35.8) 534 (34.7) 185 (32.0) 446 (39.2)
3+ 1,285 (39.5) 701 (45.6) 183 (31.6) 401 (35.3)
Postmenopausal, n (%) 2,129 (65.5) 1,033 (67.2) 380 (65.6) 716 (63.0)
Past or current hormone therapy use, n (%) 1,248 (38.4) 572 (37.2) 262 (45.3) 414 (36.4)
Body mass index 26.1 (5.4) 26.2 (5.3) 26.4 (6.1) 25.9 (5.1)
Personal history of breast cancer, n (%) 601 (18.5) 84 (5.5) 221 (38.2) 296 (26.0)
PMD 30.3 (17.6) 28.1 (16.1) 33.4 (18.2) 31.6 (18.9)
Risk factors are given as mean (SD) unless otherwise stated. PMD, percent mammographic density.
Table 3 Coefficients (standard errors) for covariates in multi-variable linear model predicting the square root of
percent mammographic density, overall and by study site
Covariate All sites together (n = 3,253) Australia (n = 1,534) Northern California
(n = 578)
Ontario
(n = 1,166)
Intercept 6.17 (0.72) 5.56 (1.00) 6.62 (1.69) 6.01 (1.33)
Age at mammogram -0.057 (0.0042) -0.056 (0.0056) -0.040 (0.011) -0.061 (0.0076)
Weight, kg -0.065 (0.0024) -0.058 (0.0034) -0.063 (0.0054) -0.074 (0.0044)
Height, cm 0.041 (0.0044) 0.041 (0.0060) 0.033 (0.103) 0.047 (0.0081)
Weight squared (centered at 70 kg) 0.00050 (6.9e-5) 0.00049 (1.1e-4) 0.00049 (1.1e-4) 0.00048 (1.4e-4)
Number of live births -0.103 (0.021) -0.100 (0.028) -0.109 (0.047) -0.096 (0.039)
Postmenopausal status -0.183 (0.076) -0.191 (0.109) -0.056 (0.185) -0.250 (0.131)
History of hormone therapy use 0.151 (0.0657) 0.133 (0.088) 0.111 (0.172) 0.090 (0.115)
Non-significant covariates (age at menarche, square of mammogram age, square of height) were removed. For the analysis by site, only the covariates in the
corresponding overall model were considered.
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cance level being 4.4. Therefore, linkage peaks of the
magnitude that we found can be expected under ran-
dom inheritance patterns, and it is unclear if these
peaks reflect true genetic linkage signals. However, our
results do provide evidence for suggestive linkage, since
our simulations showed that the empirical threshold for
suggestive linkage in these data would be 2.4.
Additional analyses
We then performed several different analyses of ancil-
lary phenotypes and subgroups to investigate whether
the evidence for linkage was stronger under different
assumptions.
Weight and height W e i g h ta n dh e i g h ta r ep a r t i a l l y
determined by genetic factors. We considered the possi-
bility that by including weight and height in the models
for calculating residuals, we may have minimized genetic
effects due to pleiotropy. Linkage was re-estimated using
residuals to models containing all predictors except
weight and height; no additional linkage peaks were
identified. Conversely, we also considered the possibility
that we were not adequately capturing the relationships
Table 4 Estimates of heritability from SOLAR (standard error)
Number of families PMD_res DA_res NDA_res
All families 1,415 0.50 (0.045) 0.50 (0.044) 0.60 (0.043)
Families from Australia 659 0.43 (0.064) 0.43 (0.062) 0.62 (0.063)
Families from Northern California 257 0.50 (0.108) 0.56 (0.105) 0.50 (0.102)
Families from Ontario 499 0.56 (0.075) 0.54 (0.076) 0.60 (0.074)
PMD_res, DA_res and NDA_res are residuals from linear models adjusting the square root of PMD, quantile-normalized dense area, and log non-dense area,
respectively, for covariates known to affect MD. MD, mammographic density; PMD percent mammographic density.
Figure 1 LOD score linkage tests across all chromosomes, for all families and Caucasian families. LOD scores at SNPs in the linkage panel
are plotted against their genetic distance (in cM) along each chromosome; chromosome boundaries are marked by vertical dashed lines. Results
are shown for (A, B and C) all families (solid black traces) and also for Caucasians (dashed red traces) for phenotypes indicated. SNP, single-
nucleotide polymorphism.
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gram in our linear models. We therefore fitted general-
ized additive models [23] for these variables, including a
bivariate smooth for weight and height, but again no
additional linkage peaks were identified.
Age It has been often argued that the influence of genes,
relative to the environment, will be larger for early onset
features or diseases. Further, it has been noted in at
least one study that three SNPs that had been reported
to be associated with breast cancer were marginally
associated with MD, but only when women with
younger ages (pre-menopausal) were considered [24].
We examined the evidence for linkage in families with
at least two sisters who were under 50 years at the time
of their mammogram, see Figure 2, to see whether link-
age signals appear stronger in this subgroup. In analysis
including only this subset of 513 pedigrees meeting this
age criterion, a modest peak seen for the PMD pheno-
type on the q arm of chromosome 7 increased in
strength (compare Figure 1A to Figure 2A), with a peak
LOD score of 3.2 (140.7 cM, 1-LOD drop interval 137.7
- 147.3, 7q32.3-7q34). It is notable that this increased
signal was identified among a much smaller number of
families (empirical genome-wide significance level P =
0.12) highlighting this chromosomal region.
Menstrual, reproductive and hormonal variables MD
decreases with age and is influenced by many factors
that alter endogenous sex hormone levels, such as the
number of pregnancies, hormone therapy use, and
menopausal status. Although in our primary analysis, we
had analyzed residuals to linear models adjusted for
these factors, we hypothesized that the magnitude of the
potential effect of a locus on MD measurements could
vary as a function of these reproductive and hormonal
variables. To explore this hypothesis, we used our linear
models with covariates to obtain a predicted PMD value
for each individual, and then we calculated the smallest
difference in predicted PMD among all pairs of sisters
in each family. We then divided the families into two
equally-sized groups based on this predicted PMD dif-
ference. Hence, in one group, age, menstrual and repro-
ductive values led to predictions of more similar PMD
Figure 2 Linkage re-analysis with an alternate covariate model for PMD or various subgroups of families. Linkage results are shown for
(A) all families with an alternate covariate (new covar.) model for PMD (yellow trace) and (A, B and C) for families containing at least two sisters
diagnosed before age 50 (black traces), families where sisters have very similar predictions (preds) of MD (grey traces), or families where sisters
have very different predictions of MD (turquoise traces) for phenotypes indicated. MD, mammographic density; PMD, percent mammographic
density.
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differences were predicted byt h ec o v a r i a t em o d e l ;t h i s
concept is illustrated in Additional file 1: supplementary
figure 6. Evidence for linkage was calculated in these
two subgroups, and results are also shown in Figure 2.
In families containing sisters with dissimilar predictions,
we saw a linkage peak for the DA phenotype on chro-
mosome 12p11.22-q13.11 (max LOD = 3.30 between
rs2061192 and rs10785424, 1-LOD drop interval from
56.0 cM - 64.0 cM, Figure 2B). Linkage in this subset
i m p l i e st h a ts h a r i n go fm a r k e r si nt h i sr e g i o ni sa s s o -
ciated with more similarity in DA, among families
where MD measures are expected to be quite variable
due to covariates. Although this analysis used the total
dense area phenotype rather than PMD, a reduced sig-
nal was also seen when we analyzed PMD (Figure 2A).
DA, like PMD, is positively associated with breast cancer
risk and may have genetic determinants that are not
shared with the non-dense area of the breast. Our signal
is within a broad linkage signal spanning an approxi-
mately 90 cM region (2-LOD drop interval) described
by Vachon and colleagues [25]. Their signal appeared to
contain two peaks, one with a maximum LOD score of
2.47 with a 1-LOD drop interval from 19 cM to 46 cM
and a second peak with a maximum LOD score of 2.45
with a 1-LOD drop interval from 55 cM to 101 cM
(Vachon, personal communication). Vachon and collea-
gues employed a model with PMD measures adjusted
for covariates but did not evaluate dense area as a sepa-
rate phenotype.
Refining the PMD phenotype To explore the impact of
phenotype-covariate modelling on the linkage results,
we refit our linear models for the square root of PMD
phenotype using a different parameterization that was
suggested by the Pike model [26]. In light of this model,
which relates cumulative exposure to ‘breast tissue age’
with breast cancer incidence rates, breast tissue age can
be expected to be greatest at menarche, to decrease
with each pregnancy, and to decline rapidly through the
menopausal period. Therefore, we defined separate cov-
ariates to estimate the decrease in PMD with each year
at each stage in life (that is, (1) between menarche and
the first live birth, (2) during the child-bearing years, (3)
post child-bearing years, and (4) post-menopause). Cov-
ariates for the number of pregnancies and use of hor-
monal therapy were included. In addition, we fit these
models using generalized estimating equations to adjust
for the effects of within-family correlation when estimat-
ing parameters. The signal on chromosome 7p is
enhanced by using these residuals for the phenotype,
with the peak at rs1029482 rising to 3.29 (1-LOD inter-
val 59.2 - 67.3 cM) (Figure 2A, new covariate model).
Eighteen percent of our simulations had a peak LOD
s c o r eo v e r3 . 5 ,t h u st h ee v i d e n c ef o rl i n k a g et ot h i s
locus is still not genome-wide ‘significant’ [27].
Association analysis
The smallest P-values obtained from the tests of within-
family association [20] are shown in Table 5; all results
for the square root of PMD residual phenotype are
s h o w ni naM a n h a t t a np l o t( F i g u r e3 ;s e ea l s oA d d i -
tional file 1: supplementary figure 7 for a QQ plot).
Using a simple Bonferroni correction for 5,677 markers,
tests for association would be considered significant at
8.8 × 10
-6. Although none of our markers showed signif-
icance at this threshold, the most significant result
(rs723149;6 7 . 7c M ;P-values 5.5 x10
-5 and 2 × 10
-4 for
PMD and DA, respectively) occurred on chromosome 7
near our linkage peak. To pursue this further, sliding
two- and three-marker haplotypes were tested for asso-
ciation using FBAT [28] around this marker, and a two
marker haplotype consisting of allele A at rs1486155
and allele A at rs723149 showed a stronger association
at P = 6.9 × 10
-7. There was weak linkage disequilibrium
between these two markers (D’ =0 . 2 0 ;2 8 1K b ) .T h e
minor allele frequency at rs723149 varies across popula-
tions http://hapmap.ncbi.nlm.nih.gov, however our test
of association using QTDT examines within-family pat-
terns of allele transmission and is robust to population
stratification. Furthermore, similar results were obtained
when we analyzed the subset of Caucasian families (not
shown).
In order to see whether the linkage signal on chromo-
some 7p was explained by this association, we imputed
haplotypes near rs723149 by using PLINK [13], and cre-
ated a covariate based on the probable count of haplo-
type AA at rs1486155 and rs723149.T h i sc o v a r i a t ew a s
then included in the linkage analysis, but was found to
have minimal impact. The LOD score fell by 0.21 for
PMD_res, from 2.69 to 2.48.
Genotype information at rs723149 of additional sets of
women with MD measurements and covariate informa-
tion was available. These included a non-overlapping set
of 235 women from Ontario and Australia [29] selected
for extreme values for MD that had been genotyped
with the Illumina Sentrix Human 1M BeadChip plat-
form and an additional group of 789 unrelated women
from Ontario (with characteristics as for the recruited
family participants) genotyped with a Taqman
® SNP
Genotyping Assay specifically for rs723149. No evidence
for association with PMD was observed in these 1,024
women (MAF = 0.42, linear regression with 0,1, 2 cod-
ing for number of copies of allele A, b = -0.077 (SE =
0.083), P = 0.35, for association with the square root of
PMD adjusted for age, age squared, weight, weight
squared, height, height squared, parity, and menopausal
status).
Greenwood et al. Breast Cancer Research 2011, 13:R132
http://breast-cancer-research.com/content/13/6/R132
Page 8 of 13Discussion
Phenotype definition is critical in linkage analysis. The
extent of MD can be measured by the percent of the
breast that is dense or by the total area that is dense.
DA is highly correlated with PMD, but has a skewed
distribution. Nevertheless, after transformation and
adjustment for covariates, repeated reads of the same
mammogram showed very high correlations for DA and
for PMD. Therefore, we examined the evidence for link-
age to both these phenotypes, and found evidence for
suggestive linkage at multiple locations. Furthermore,
since MD is known to vary through life, genes that
appear to influence MD in mid-life could reflect early
influences on MD at the time the breast forms in ado-
lescence, or through subsequent changes or rates of
change with increasing age, parity and the menopause,
or through influences on both formation and age change
in MD [30]. Our study was designed so that there was
rarely more than five years difference between the ages
at mammogram for sister pairs in a family; hence the
study was partially matched within families for the large
effect of age on MD. In addition, MD measures were
adjusted for age prior to linkage analysis.
Given the number of study participants and available
pedigree information, we had estimated that we would
have 80% power to obtain a LOD score in the range of
3 with a locus that could explain 25% of the heritability
of PMD. Despite the large collection of families and
careful consideration of mammographic density para-
meters, our primary linkage analysis did not yield LOD
scores that exceeded desired thresholds set by genome-
wide gene-dropping simulations. With different model-
ing conditions, three loci on chromosomes 7p14.1-p13,
12p11.22-q13.11, and 7q32.3-q34, showed LOD scores
Table 5 Selected tests of within-family association with at least one phenotype with P-value ≤0
Chromosome Marker Nucleotide position Minor allele/MAF in our data PMD_res DA_res NDA_res Allele with higher MD
1 rs1526480 91,209,986 0.39 (G) 0.041 0.71 4.00e-4 A
2 rs715271 57,133,410 0.32 (C) 5.00e-4 0.0019 0.024 A
7 rs723149 46,543,581 0.43 (A) 5.50e-5 2.00e-4 0.035 A
8 rs4317547 141,285,098 0.27 (A) 7.77e-5 .0016 2.00e-4 A
12 rs1012315 97,639,144 0.29 (A) 3.00e-4 7.00e-4 0.018 G
14 rs764602 49,480,419 0.48 (A) 0.022 0.35 3.00e-4 G
14 rs1959064 57,044,005 0.32 (G) 0.036 2.00e-4 0.045 A
20 rs7272911 35,946,239 0.30 (A) 0.0041 0.091 1.00e-4 G
0 500 1000 1500 2000 2500 3000
0
1
2
3
4
5
6
MB
−
l
o
g
(
1
0
)
 
p
−
v
a
l
u
e
s
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
● ●
●
● ●
●
●
●
● ● ●
●
●
●
●
●
●
●
●
● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ● ●
●
● ● ● ●
●
●
● ●
● ●
●
●
● ●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
● ●
●
● ●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ●
●
●
● ●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
● ●
●
●
● ●
●
● ●
●
●
●
●
●
●
●
●
● ●
●
●
● ●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
● ● ●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
● ●
●
●
●
●
● ● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
● ●
●
● ●
●
●
● ● ●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
● ●
● ●
●
●
●
●
●
●
● ●
● ●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
● ● ●
●
● ● ●
●
●
●
●
●
●
●
● ●
●
● ●
●
● ●
●
● ●
● ●
●
● ●
●
●
●
●
●
●
● ●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ● ● ●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
● ●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
● ●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
● ● ●
●
● ●
●
●
●
●
●
●
● ●
●
● ●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
● ●
●
● ● ●
●
●
● ● ●
● ●
●
●
●
●
●
●
●
●
● ● ●
●
●
● ●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
● ●
●
●
●
● ●
●
●
●
●
●
● ●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
● ●
● ●
●
●
●
●
●
● ● ●
● ● ●
● ●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
● ●
●
●
● ●
●
● ●
●
●
●
●
●
● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
● ●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
● ● ● ● ●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
● ●
● ●
●
●
●
● ●
● ●
●
●
● ●
● ● ● ● ● ●
●
● ● ● ● ●
●
●
●
● ●
●
●
●
●
● ●
●
●
● ●
●
●
● ● ●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
● ●
● ●
● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
● ●
●
● ●
●
●
●
●
● ●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
● ●
●
● ●
●
●
●
●
●
●
●
●
● ● ●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
● ●
●
●
●
●
●
●
●
●
●
●
● ●
●
● ● ●
●
●
●
●
●
●
●
●
● ●
●
●
●
● ● ●
●
● ●
●
●
●
●
● ●
●
●
● ●
●
● ●
● ●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
● ● ● ●
●
●
●
●
●
● ●
●
●
●
●
● ●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
● ●
●
●
●
●
● ● ●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
● ● ●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ●
●
● ●
● ● ●
●
●
●
●
●
●
● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
● ●
●
●
●
●
● ●
●
● ●
●
●
●
●
●
●
● ●
●
●
● ●
●
●
●
●
●
● ●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
● ●
● ●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
● ●
●
●
●
● ● ●
●
●
●
●
●
●
● ●
● ● ●
●
● ●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
● ●
●
●
●
●
● ●
●
● ●
●
●
●
●
●
●
●
●
● ●
●
●
●
● ●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
● ●
●
●
●
●
●
● ●
●
●
●
●
●
● ●
●
●
● ●
●
● ●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
● ● ●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ●
●
●
●
●
●
● ● ●
●
●
●
●
● ●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
● ● ●
● ●
●
●
●
●
● ●
●
●
●
●
●
● ● ●
●
●
●
●
●
●
●
● ● ●
●
●
● ●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
● ● ●
●
●
●
●
● ●
●
● ●
●
●
●
●
●
●
●
●
●
●
● ● ●
●
● ●
●
●
● ●
● ●
●
●
●
●
●
●
● ●
●
● ●
●
●
●
●
●
●
●
●
●
● ●
●
●
● ●
●
●
●
● ● ● ●
●
●
●
●
● ●
●
●
●
●
●
●
●
● ●
● ●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
● ●
●
● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
● ● ●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
● ●
●
● ●
● ● ●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ●
●
●
●
● ●
●
●
●
●
● ●
●
●
●
● ●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
● ●
●
●
●
● ●
● ●
●
● ●
●
● ● ● ● ●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ● ●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
● ●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
● ●
● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
● ● ●
● ●
●
● ●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
● ●
● ● ●
●
●
● ●
●
●
●
●
●
●
●
●
●
● ● ●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
● ●
● ● ●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
● ●
●
●
●
●
●
●
●
●
●
● ● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
● ●
●
●
●
●
● ● ● ●
●
●
●
●
●
●
● ●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
● ●
● ●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
● ● ●
●
●
●
●
●
●
●
●
● ●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
● ●
●
●
●
●
● ●
●
● ●
●
●
● ●
●
●
●
●
● ● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
● ●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
● ●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
● ●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
● ●
●
●
●
●
●
● ●
●
●
●
●
● ●
●
●
● ● ●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
● ●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
● ●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
● ● ●
●
●
●
●
●
●
●
● ●
● ●
●
●
●
●
●
●
●
●
● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
● ● ●
● ●
●
●
●
●
●
●
●
●
●
●
● ● ●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
● ●
●
● ●
●
●
●
●
●
●
● ● ●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ●
●
●
● ●
●
●
● ●
●
●
●
● ●
●
●
●
●
●
● ●
●
● ●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
● ●
●
●
●
●
●
●
● ●
● ●
●
●
●
● ●
● ●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ●
●
●
● ● ●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
● ● ●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
● ●
● ●
● ●
●
●
● ●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
● ● ●
●
●
●
●
●
● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
Figure 3 Manhattan plot of association test results for the square root of PMD residuals. P-values (-log10) of association tests using the
orthogonal model of QTDT are plotted against physical position across the chromosomes. A Bonferroni correction for 5677 tests would lead to
a threshold of 5.05 for significance at a = 0.05. PMD, percent mammographic density.
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Page 9 of 13that approach or exceed 3. However, given that these
results were obtained after multiple analyses, these sig-
nals should be considered as ‘suggestive’.
Chromosome 7p: With the development of a model
for covariate effects that was inspired by Pike and col-
leagues [26], evidence for linkage increased on chromo-
some 7p, with a maximum LOD score of 3.29. This
increase associated with a more careful phenotype defi-
nition is suggestive that there may be loci influencing
aspects of MD or MD changes, but also that the ideal
parameterization for MD is still unknown. The 1-LOD
drop interval bounded by rs1949880 and rs2054789 cor-
responds to a 7.2 Mb region containing 72 genes,
including small clusters of snoRNA and piRNA genes
toward its proximal boundary. Of interest at the proxi-
mal boundary, are the insulin-like growth factor binding
protein genes, IGFBP1 and IGFBP3, both of which have
been hypothesized to be involved in mammographic
density (and in breast cancer and other cancers) and
have been considered in previous association studies
examining MD phenotypes [31-35]. Of these, two stu-
dies included more than 1,000 unrelated women [32,3]
with investigation of the common genetic variation in
these genes, but they did not reveal consistent evidence
of association with MD phenotypes. Also, a recent
meta-analysis of 4,877 women did not identify associa-
tion with MD in this region [29]. As linkage analysis
may be less sensitive to allele frequency issues, these
genes remain as interesting candidates. Another gene of
potential interest within this region includes the ras-
related gene, v-ral simian leukemia viral oncogene
homolog A (RALA) with its implicated role in signalling
and growth.
Chromosome 7q: When we examined families con-
taining younger sisters (two sisters with mammograms
under age 50 years), the peak on chromosome 7q
became stronger. This peak with a 1-LOD drop interval
bounded by rs4728251 and rs1476640, corresponds to
9.6 Mb containing 69 genes. Phenotypes at younger ages
are expected to display a stronger genetic component
[36] but there was no evidence that PMD h
2 varied by
age in our previous twin studies [30,37], and thus age
should continue to be considered in future studies. A
gene of potential interest within this region is a member
of the RAS oncogene family, RAB19.
Chromosome 12: On chromosome 12, a maximum
LOD score of 3.3 was seen in families where the sisters
would be expected to have dissimilar DA, after adjust-
ment for factors affecting sex hormone levels. Such pre-
dicted differences could be due to: differences in the
numbers of pregnancies; ages at menopause or
menarche; weight; or height. Linkage in this context
would identify families where phenotypes are more simi-
lar than expected, and this could imply a larger potential
genetic effect. The 1-LOD interval of our linkage signal,
bounded by rs1909160 and rs1978161 corresponds to a
large physical distance of 16.7 Mb encompassing the
centromere and contains 80 genes. Genes of potential
interest within this region include the vitamin D recep-
tor (VDR) and collagen type II (COL2A1) given their
association to breast biology.
We did not detect any significant evidence for linkage
on chromosome 5 as was reported in a previous study
of 89 multi-generation pedigrees [25], which, like our
study, included mostly Caucasian women; however,
there may have been differences in the family ancestries
or characteristics of the source populations that are not
obvious.
That high mammographic density is associated with
risk for breast cancer motivated our study, with antici-
pation that some gene determinants of MD may be can-
didates for involvement or development of malignancy
[29]. Many groups have pursued genome-wide linkage
studies for breast cancer using non-BRCA1/2 high risk
families, more recently with families of confined ances-
tries (see [38], and within) after family sets of diverse
origins did not yield strong linkage signals [39,40]. Sug-
g e s t i v ee v i d e n c ef o rac h r o m o s o m e7l o c u sw a si d e n t i -
fied in one study [39], however, this region is more
proximal occurring at 7q21.11-q21.3, and does not over-
lap with the suggestive MD locus detected in our
younger women set. Large scale association studies have
also been carried out, several with discovery or first-
stage study sizes that exceed 1,000 cases of breast cancer
[41-46] leading to loci for consideration, with consider-
able family risk remaining to be explained [45]. We note
that none of our suggestive linkage peaks observed coin-
cide with the candidate genes and their local SNPs that
reached genome-wide significance in these large studies.
Conclusions
Despite a reliable and plausible intermediate phenotype
for breast cancer risk, we were unable to identify new
loci with a strong influence on MD, nor could we con-
firm a previously reported region on chromosome 5p13-
p14. However, we did identify signals on chromosomes
7p, 7q, and 12 that warrant further investigation. Nota-
bly, the evidence for linkage among younger women on
7q, as well as thepeak on chromosome 12 overlapping a
previously-identified region may prove to be interesting.
Additional material
Additional file 1: Supplementary Figures and Tables. Supplementary
Table 1. Recruitment of families for linkage with details of Ontario
studies. Supplementary Table 2. Family characteristics. Supplementary
Table 3. Breast cancer rates among women with complete data, by study
type. Supplementary Table 4. Coefficients (standard errors) for covariates
in multi-variable linear models predicting DA and NDA, all three sites
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Page 10 of 13together. Supplementary Figure 1. Participant recruitment by site.
Supplementary Figure 2. Reliability of mammographic density scoring.
Supplementary Figure 3. Data cleaning for genetic analysis.
Supplementary Figure 4. Principal component analysis of study
participants. Supplementary Figure 5. QQ plot of tests of Hardy-Weinberg
equilibrium. Supplementary Figure 6. Illustration of the division of families
into two groups as a function of predicted mammographic density.
Supplementary Figure 7. QQ plot of association tests for the residuals
from a linear model for the square root of PMD.
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